Related Experiment Video
Updated: Jul 9, 2026
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.9K
CAR-T cells: the Chinese experience
Linqin Wang1,2,3, Elaine Tan Su Yin1,2,3, Houli Zhao1,2,3
1Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou, China.
Expert Opinion on Biological Therapy
|July 2, 2020
Summary
China is a global leader in Chimeric antigen receptor T (CAR-T) cell therapy clinical trials, focusing on novel targets and optimized CAR structures. This research drives advancements in treating hematological malignancies and solid tumors.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor T (CAR-T) cell therapy offers targeted cancer cell lysis, improving outcomes for relapsed or refractory (R/R) hematological malignancies and some solid tumors.
- China is significantly expanding its clinical trials for novel CAR-T therapeutic strategies.
Purpose of the Study:
- To summarize and evaluate registered CAR-T clinical trials conducted in China.
- To analyze trial distribution, phases, CAR structures, target antigens, and diseases studied.
- To detail the efficacy, toxicity, and optimization strategies in Chinese CAR-T studies.
Main Methods:
- Systematic review of registered CAR-T clinical trials in China.
- Evaluation of trial parameters including study phase, CAR design, and target antigens.
- Analysis of reported efficacy, toxicity, and novel therapeutic strategies.
Main Results:
- China ranks second globally in CAR-T clinical trials, accounting for approximately 33% of worldwide trials.
- Extensive research in China focuses on novel target antigens, CAR structure optimization, and combination therapies.
- Chinese studies are exploring expanded applications of CAR-T cell therapy.
Conclusions:
- China's extensive CAR-T clinical trial activities signal significant progress and innovation in the field.
- Ongoing research in China is poised to revolutionize CAR-T therapy for various cancers.
- The focus on optimization and novel strategies suggests a promising future for CAR-T treatments developed in China.
